RxDoctor Payments Data

Bart Worthington, DO

Family Medicine · North Pole, AKNPI 1205274347

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AbbVie at 45.7% of the total. Reporting peaked in 2023 at $278 and has fallen 81.8% since, to $51 in 2025.

$847in general payments, 2019–2025

Across 32 payments — averaging $26.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$387
  • AstraZeneca$324
  • Sanofi-aventis U.S. LLC$47
  • Amarin Pharma, Inc.$18
  • Echosens North America, Inc.$18
  • Novo Nordisk$18
  • plus $35 from 2 others

What the payments were for

  • Food & beverage$847100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$847 in reported general payments places this provider in the 80th percentile of 334 family medicine providers in Alaska.

See all family medicine providers in Alaska

Medicare billing

Part B allowed, 2024
$151,680
Medicare patients
294
Services billed
2,236

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin40$50,398
OzempicSemaglutide26$28,799
EliquisApixaban29$25,007
CreonLipase/Protease/Amylase16$22,349
TrulicityDulaglutide11$11,479
Testosterone15$4,725
MenostarEstradiol12$2,200
Rosuvastatin Calcium83$1,856
Tolterodine Tartrate ErTolterodine Tartrate19$1,656
SynthroidLevothyroxine Sodium11$1,374
Lidocaine15$1,317
Atorvastatin Calcium106$953
Albuterol Sulfate HfaAlbuterol Sulfate24$947
Levothyroxine Sodium88$931
Metoprolol Succinate50$889

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$18$28,79926 claims
AbbVieCreon, Synthroid$387$23,72427 claims
Lilly USA, LLCTrulicity$17$11,47911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 334 family medicine providers in Alaska.

Other family medicine in North Pole

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →